Logo image of GH

GUARDANT HEALTH INC (GH) Stock Fundamental Analysis

NASDAQ:GH - Nasdaq - US40131M1099 - Common Stock - Currency: USD

41.42  +0.44 (+1.07%)

After market: 41.42 0 (0%)

Fundamental Rating

2

Overall GH gets a fundamental rating of 2 out of 10. We evaluated GH against 103 industry peers in the Health Care Providers & Services industry. GH has a bad profitability rating. Also its financial health evaluation is rather negative. GH is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year GH has reported negative net income.
GH had a negative operating cash flow in the past year.
In the past 5 years GH always reported negative net income.
In the past 5 years GH always reported negative operating cash flow.
GH Yearly Net Income VS EBIT VS OCF VS FCFGH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

With a Return On Assets value of -31.02%, GH is not doing good in the industry: 88.35% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -31.02%
ROE N/A
ROIC N/A
ROA(3y)-32.29%
ROA(5y)-25.29%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GH Yearly ROA, ROE, ROICGH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800 -1K

1.3 Margins

GH's Gross Margin of 61.34% is amongst the best of the industry. GH outperforms 83.50% of its industry peers.
GH's Gross Margin has declined in the last couple of years.
GH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.34%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.32%
GM growth 5Y-1.93%
GH Yearly Profit, Operating, Gross MarginsGH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

3

2. Health

2.1 Basic Checks

GH does not have a ROIC to compare to the WACC, probably because it is not profitable.
GH has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, GH has more shares outstanding
Compared to 1 year ago, GH has a worse debt to assets ratio.
GH Yearly Shares OutstandingGH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
GH Yearly Total Debt VS Total AssetsGH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

Based on the Altman-Z score of -0.79, we must say that GH is in the distress zone and has some risk of bankruptcy.
GH's Altman-Z score of -0.79 is on the low side compared to the rest of the industry. GH is outperformed by 82.52% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -0.79
ROIC/WACCN/A
WACC8.12%
GH Yearly LT Debt VS Equity VS FCFGH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

A Current Ratio of 4.11 indicates that GH has no problem at all paying its short term obligations.
GH has a Current ratio of 4.11. This is amongst the best in the industry. GH outperforms 92.23% of its industry peers.
A Quick Ratio of 3.76 indicates that GH has no problem at all paying its short term obligations.
GH has a Quick ratio of 3.76. This is amongst the best in the industry. GH outperforms 90.29% of its industry peers.
Industry RankSector Rank
Current Ratio 4.11
Quick Ratio 3.76
GH Yearly Current Assets VS Current LiabilitesGH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

6

3. Growth

3.1 Past

The earnings per share for GH have decreased by -1.19% in the last year.
Looking at the last year, GH shows a very strong growth in Revenue. The Revenue has grown by 31.04%.
The Revenue has been growing by 28.08% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-1.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.76%
Revenue 1Y (TTM)31.04%
Revenue growth 3Y25.52%
Revenue growth 5Y28.08%
Sales Q2Q%30.95%

3.2 Future

GH is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.78% yearly.
Based on estimates for the next years, GH will show a quite strong growth in Revenue. The Revenue will grow by 19.12% on average per year.
EPS Next Y11.41%
EPS Next 2Y11.55%
EPS Next 3Y12.17%
EPS Next 5Y16.78%
Revenue Next Year21.39%
Revenue Next 2Y21.41%
Revenue Next 3Y22.07%
Revenue Next 5Y19.12%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
GH Yearly Revenue VS EstimatesGH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
GH Yearly EPS VS EstimatesGH Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 6 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

GH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GH Price Earnings VS Forward Price EarningsGH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GH Per share dataGH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

A more expensive valuation may be justified as GH's earnings are expected to grow with 12.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.55%
EPS Next 3Y12.17%

More info and screens

0

5. Dividend

5.1 Amount

GH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GUARDANT HEALTH INC

NASDAQ:GH (8/1/2025, 8:00:00 PM)

After market: 41.42 0 (0%)

41.42

+0.44 (+1.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)07-30 2025-07-30/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners99.8%
Inst Owner Change-0.06%
Ins Owners4.65%
Ins Owner Change-0.5%
Market Cap5.13B
Analysts84.85
Price Target59.6 (43.89%)
Short Float %8.11%
Short Ratio4.82
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.25%
Min EPS beat(2)-18.05%
Max EPS beat(2)1.54%
EPS beat(4)1
Avg EPS beat(4)-10.27%
Min EPS beat(4)-18.05%
Max EPS beat(4)1.54%
EPS beat(8)4
Avg EPS beat(8)3.19%
EPS beat(12)6
Avg EPS beat(12)1.4%
EPS beat(16)8
Avg EPS beat(16)1.67%
Revenue beat(2)2
Avg Revenue beat(2)2.94%
Min Revenue beat(2)1.97%
Max Revenue beat(2)3.91%
Revenue beat(4)4
Avg Revenue beat(4)5.15%
Min Revenue beat(4)1.97%
Max Revenue beat(4)8.95%
Revenue beat(8)8
Avg Revenue beat(8)4.22%
Revenue beat(12)10
Avg Revenue beat(12)3.07%
Revenue beat(16)12
Avg Revenue beat(16)2.89%
PT rev (1m)0.12%
PT rev (3m)5.69%
EPS NQ rev (1m)0.25%
EPS NQ rev (3m)-3.96%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.43%
Revenue NQ rev (1m)-0.01%
Revenue NQ rev (3m)2.6%
Revenue NY rev (1m)0.19%
Revenue NY rev (3m)3.21%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.63
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.4
EYN/A
EPS(NY)-2.69
Fwd EYN/A
FCF(TTM)-2.46
FCFYN/A
OCF(TTM)-2.2
OCFYN/A
SpS6.25
BVpS-2.02
TBVpS-2.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.02%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.34%
FCFM N/A
ROA(3y)-32.29%
ROA(5y)-25.29%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.32%
GM growth 5Y-1.93%
F-Score4
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 78.36%
Cap/Sales 4.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.11
Quick Ratio 3.76
Altman-Z -0.79
F-Score4
WACC8.12%
ROIC/WACCN/A
Cap/Depr(3y)115.32%
Cap/Depr(5y)203.86%
Cap/Sales(3y)8.54%
Cap/Sales(5y)12.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.76%
EPS Next Y11.41%
EPS Next 2Y11.55%
EPS Next 3Y12.17%
EPS Next 5Y16.78%
Revenue 1Y (TTM)31.04%
Revenue growth 3Y25.52%
Revenue growth 5Y28.08%
Sales Q2Q%30.95%
Revenue Next Year21.39%
Revenue Next 2Y21.41%
Revenue Next 3Y22.07%
Revenue Next 5Y19.12%
EBIT growth 1Y14.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year40.62%
EBIT Next 3Y21.22%
EBIT Next 5Y23.63%
FCF growth 1Y26.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y23.29%
OCF growth 3YN/A
OCF growth 5YN/A